(Q40632672)

22 September 2017

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease (English)

1 reference

22 September 2017

0 references

1 reference

1 reference

7

Joseph H Friedman

1 reference

22 September 2017

Alan Breier

1

1 reference

22 September 2017

Virginia K Sutton

2

1 reference

22 September 2017

Peter D Feldman

3

1 reference

22 September 2017

Deborah L Kadam

4

1 reference

22 September 2017

Iris Ferchland

5

1 reference

22 September 2017

Padraig Wright

6

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

22 September 2017

Biological Psychiatry

1 reference

22 September 2017

52

1 reference

22 September 2017

438-445

1 reference

22 September 2017

5

1 reference

Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Clozapine for the treatment of psychosis in Parkinson's disease: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Psychotic complications of long-term levodopa treatment of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Objective changes in motor function during placebo treatment in PD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

CLOZAPINE AND AGRANULOCYTOSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Parkinsonism: onset, progression, and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Letter: Clozapine and agranulocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Guidelines on drug treatments for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

How much of the placebo ‘effect’ is really statistical regression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Worsening of motor function in Parkinson's disease: a "typical" response to "atypical" antipsychotic medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Worsening of motor features of parkinsonism with olanzapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

A danger in making the diagnosis of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

inferred from DOI database lookup

7 January 2021

based on heuristic

The Management of the Levodopa Psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901392-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(02)01392-6

1 reference

22 September 2017

1 reference